Vesicare (solifenacin) / Astellas - LARVOL DELTA

Hypogammaglobulinaemia (HG), Infection Risks and Effects of Immunoglobulin Replacement Therapy (IgG RT) in Multiple Myeloma (MM): A Registry Based Longitudinal Real-World-Analysis (RWA) (IMS 2026) - "While pre-emptive IgG RT is standard in deeply immunosuppressive therapies (e.g. bispec... HG and even more sHG are frequent complications in MM pts. with all types of effective anti-myeloma therapies resulting in high rates of infections per pt./year with a hazard rate of 3,31 in sHG. The most important risk factors are: the use of anti-CD8 antibodies, an ECOG ≥ 2, status post ASCT within 6 mo., number of previous therapies and age."

Clinical • Real-world • Real-world evidence • Geriatric Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • CD8

Oral solifenacin suspension in the management valve bladder: a pilot study. (PubMed, World J Urol) - "This pilot study reports the efficacy, safety, and tolerability of oral suspension form of solifenacin in children with valve bladder. Further larger studies are warranted."

Journal • Infectious Disease • Nephrology • Urology

Exploring the therapeutic potential of Beta-3 adrenergic agonists in overactive bladder: A comparative analysis of monotherapy versus combination therapy strategies. (PubMed, Wiad Lek) - " Beta-3 agonist as monotherapy is a potent, multimodality first-line therapy with strong influence of severe disease. Each of combinatory treatments show characteristic effect on phenotype-specific increase in bladder capacity. Mirabegron flaoxate could be considered for detrusor hypertrophy and combination of mirabegron Solifenacin would stimulate voiding facilitate. These proof of concept data justify PPTP based on objective biomarkers such as BWT and PVR to select combination therapy in what is another small step in our journey towards precision medicine for OAB."

Clinical • Journal • Monotherapy • Observational data • Overactive Bladder

Modulation of voltage-dependent K+ channel activity by the muscarinic receptor antagonist solifenacin in native coronary arterial smooth muscle cells. (PubMed, Korean J Physiol Pharmacol) - "These results indicate that solifenacin targets multiple Shaker-related (Kv1.x) channel subtypes, with Kv1.5 making a substantial contribution to the observed current suppression. Solifenacin inhibits arterial Kv channels in a concentration- and use (inactivated state)-dependent manner by modulating inactivation gating, predominantly involving the Kv1.5 subtype."

Journal

Sex- and Age-Specific Trends in Prescriptions of Beta-3 Agonists and Anticholinergics in Japan: A Nationwide Prescription Database Study. (PubMed, Low Urin Tract Symptoms) - "A nationwide shift in overactive bladder treatment, where the growth in β3-agonist prescriptions outweighed the decline in anticholinergics, was observed across all demographic groups in Japan."

Journal • Overactive Bladder

M3 muscarinic receptor antagonism attenuates cocaine-induced hippocampal oligodendroglial changes and relapse-like behavior in male mice. (PubMed, Neuropharmacology) - "Adult male C57BL/6J mice were subjected to cocaine-conditioned place preference (CPP), extinction, and cocaine-primed reinstatement, and treated with benztropine (BZT), the M1-selective mAChR antagonist VU0255035, or the M3-preferential mAChR antagonist solifenacin (SOL). In CD140a-sorted oligodendrocyte precursor cell-derived cultures, SOL increased MBP-positive oligodendrocyte volume relative to cocaine alone; however, the lack of a SOL-VU0255035 difference precluded conclusions about subtype specificity. These findings provide evidence consistent with a contribution of M3-sensitive muscarinic mechanisms to cocaine-associated oligodendroglial and behavioral alterations."

Journal • Preclinical • Solid Tumor • CHRM3 • MBP • OLIG2 • PDGFRA • SLC6A3

Reply to Editorial Comment on "Quantitative assessment of additive effects of mirabegron and solifenacin in overactive bladder: re-analysis of SYNERGY study". (PubMed, Urology) - No abstract available

Journal • Overactive Bladder

Urine Epidermal Growth Factor/Creatinine Ratio in Female Patients with Overactive Bladder and Recurrent Lower Urinary Tract Infection. (PubMed, Gynecol Minim Invasive Ther) - "Patients with OAB were treated with either mirabegron (Betmiga®) or solifenacin succinate (Vesicare®) for 3 months. No significant difference in urine EGF/creatinine ratio was observed between control subjects and patients with OAB or recurrent lower UTI. Thus, urine EGF is not likely a useful marker for distinguishing between OAB and recurrent lower UTI."

Journal • Infectious Disease • Nephrology • Overactive Bladder • Xerostomia • EGF

Second- and third-line treatment options for refractory monosymptomatic enuresis in children: a scoping review. (PubMed, Eur J Pediatr) - "The results showed that, following first-line treatment, a combination of biofeedback, electrical nerve stimulations, anticholinergics (e.g. oxybutynin, tolterodine, solifenacin), β3-adrenoceptor agonists (e.g. vibegron), tricyclic antidepressants (e.g. imipramine) and selective serotonin reuptake inhibitor (e.g. fluoxetine) improved both partial response (PR) and complete response (CR) at varying rates across highly heterogeneous interventions and study populations...Furthermore, reports on electro-acupuncture, furosemide, onabotulinumtoxin A injections or the herbal medicine 'shokenchuto' were considered unreliable for pure refractory MNE, despite improvements in PR and CR occurring at different rates...Some second- and third-line treatment options may improve PR and CR rates, despite the limited available evidence to support a treatment algorithm. However, further research is needed to confirm these benefits."

Clinical • Journal • Review • Pediatrics • Urinary Incontinence

Editorial Comment on "Quantitative assessment of additive effects ofmirabegrin and solifenacin in overactive bladder: re-analysis of SYNERGY study". (PubMed, Urology) - No abstract available

Journal • Overactive Bladder

The efficacy of PTNS in the treatment of refractory POAB (ChiCTR) - P=N/A | N=252 | Completed | Sponsor: The Second Affiliated Hospital of Wenzhou Medical University; The Second Affiliated Hospital of Wenzhou Medical University

New trial • Overactive Bladder • Pediatrics

BEAM: Burden and Efficacy of Anticholinergic vs Mirabegron in Overactive Bladder - A Randomized Controlled Study (clinicaltrials.gov) - P4 | N=208 | Not yet recruiting | Sponsor: Universidade do Porto

New P4 trial • Overactive Bladder

A Study to Track the Safety of Vesomni in Men in South Korea Treated in Routine Clinical Practice for the Urinary Symptoms of Benign Prostatic Hyperplasia (Enlarged Prostate) (clinicaltrials.gov) - P=N/A | N=600 | Not yet recruiting | Sponsor: Astellas Pharma Korea, Inc. | Initiation date: Jun 2026 ➔ Sep 2026

Monotherapy • Trial initiation date • Benign Prostatic Hyperplasia

Quantitative assessment of additive effects of mirabegron and solifenacin in overactive bladder: re-analysis of SYNERGY study. (PubMed, Urology) - "The efficacy of mirabegron-solifenacin combination therapy in OAB seems to be explained by additive IDA. Its clinical value lies in additive symptom control with preserved tolerability rather than synergistic interaction."

Journal • Overactive Bladder • Urinary Incontinence • Urology

Long-term efficacy and safety of solifenacin, mirabegron, and their combination for overactive bladder: a systematic review. (PubMed, Front Pharmacol) - "However, these findings cannot be generalized to other muscarinic receptor antagonists or β3-adrenoceptor agonists. https://www.crd.york.ac.uk/PROSPERO/view/CRD420251056532, identifier CRD420251056532."

Journal • Review • Constipation • Gastroenterology • Gastrointestinal Disorder • Overactive Bladder • Xerostomia

Medication Burden: Beyond Counts to Recognize Polypharmacy as an Inherent Part of Living With Chronic Kidney Disease. (PubMed, Basic Clin Pharmacol Toxicol) - "Proton pump inhibitors (PPIs), opioids and non-benzodiazepine hypnotics (Z-drugs) were identified as common PIMs, whereas bladder antimuscarinics (tolterodine and solifenacin), sedating antihistamines (clemastine and promethazine) and antipsychotics with anticholinergic properties (quetiapine) were the most frequently used medications with strong anticholinergic properties. In conclusion, medication burden in patients with CKD is high, and incorporating PIMs and ACB scores may identify prescribing risks not captured by medication counts alone."

Journal • Retrospective data • Chronic Kidney Disease • CNS Disorders • Nephrology • Renal Disease

Pharmacological Management of Stress Urinary Incontinence with Atypical Leakage Features, Symptom Response to Short-Term Solifenacin Trial. (PubMed, Int Urogynecol J) - No abstract available

Journal • Urinary Incontinence • Urology

Comparative efficacy of transcutaneous tibial nerve stimulation (TTNS) versus solifenacin in female patients with overactive bladder. (PubMed, BMC Urol) - "TNS is an effective and well-tolerated treatment for OAB, offering superior improvement in urinary incontinence and a markedly better safety profile compared with solifenacin. TNS may represent a preferable non-pharmacologic alternative for patients who cannot tolerate or do not respond adequately to anticholinergic medications. Future studies with larger cohorts and extended follow-up durations would be beneficial to validate and expand upon our findings."

Clinical • Journal • Overactive Bladder • Urinary Incontinence • Urology

Strategy for Withdrawal of Pharmacological Treatment for Urinary Incontinence in Children (StayDry) (clinicaltrials.gov) - P4 | N=216 | Active, not recruiting | Sponsor: University of Aarhus | Recruiting ➔ Active, not recruiting

Enrollment closed • Urinary Incontinence • Urology

A Study to Track the Safety of Vesomni in Men in South Korea Treated in Routine Clinical Practice for the Urinary Symptoms of Benign Prostatic Hyperplasia (Enlarged Prostate) (clinicaltrials.gov) - P=N/A | N=600 | Not yet recruiting | Sponsor: Astellas Pharma Korea, Inc.

Monotherapy • New trial • Benign Prostatic Hyperplasia

Comment on "Pharmacological Management of Stress Urinary Incontinence with Atypical Leakage Features, Symptom Response to Short-term Solifenacin Trial". (PubMed, Int Urogynecol J) - No abstract available

Journal • Urinary Incontinence • Urology

MEL-SOL-STENT: Melatonin and Solifenacin for Double-J Ureteral Stent Symptoms (clinicaltrials.gov) - P2 | N=189 | Recruiting | Sponsor: Beni-Suef University

HEOR • New P2 trial • Renal Calculi • Urolithiasis

Exploring the role of urinary brain-derived neurotrophic factor in diagnosis and follow-up of overactive bladder in women: A prospective analytical study in a tertiary care center experience. (PubMed, Asian J Urol) - "Following a 3-month treatment period with solifenacin, a statistically significant reduction was found in the urinary BDNF/creatinine ratio of the OAB group to a mean of 8.2 (SD 3.7) pg/mg, ranging from 2.2 to 14.7 pg/mg (paired samples t-test, p<0.001). BDNF can be used to assess the presence of OAB and follow up the course of OAB as a supplementary tool to clinical assessment and urodynamics."

Journal • Overactive Bladder • Urology • BDNF

Comparative Analysis of Solifenacin Plus Desmopressin Versus Desmopressin Alone in the Treatment of Primary Mono Symptomatic Nocturnal Enuresis (AUA 2026) - "Our study demonstrated that the combination of Solifenacin plus Desmopressin is more effective than desmopressin monotherapy in the treatment of PMNE with an acceptable tolerability profile."

Urinary Incontinence

Analysis of Temporal Trends in Anticholinergic and ß3 Agonist Prescription Patterns in the United States Pediatric Population (AUA 2026) - "Annual rates and cost of anticholinergic (darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, trospium) and β3 agonist (mirabegron, vibegron) prescriptions were determined by drug type and insurance. Anticholinergic prescription rates in children decreased, with rates in the Medicaid and commercially insured populations converging. β3 agonist prescription rates were low but increased substantially and were higher among commercially insured patients. Anticholinergic costs were similar between groups, while β3 agonist prescriptions cost nearly twice as much for commercially insured patients."

Clinical • Alzheimer's Disease • CNS Disorders • Dementia • Overactive Bladder • Pediatrics